Doxorubicin-Induced Cardiomyopathy

By M. Runge, G. Stouffer, R. Sheahan, F. Otero, P. Boor. 2000

849 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/6f76300dc67185e28fa1b060154ca6328dd13d7f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Cellular senescence promotes adverse effects of chemotherapy and cancer relapse (2016, background): “One major limitation to the Doxo dose that can be given to patients is cardiotoxicity, largely due to thickening of the left ventricle wall (22).”
A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. (2014, background): “We next investigated whether iRGD-Exos-Dox therapy caused cardiac damage, the most important dose-limiting side effect of Dox [19].”
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (2012, neutral): “Serial echocardiographic monitoring is generally used for cardio-toxicity detection [12].”
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. (2004, background): “However, all patients were followed clinically for signs and symptoms of CHF. bPatients in the PLD arm had a median cumulative anthracycline dose of 293 mg/m2 (including prior anthracycline exposure). cPatients in the conventional doxorubicin arm had a median cumulative anthracycline dose of 361 mg/”
Ferroptosis: mechanisms and links with diseases (2021, background): “Other pathological conditions Doxorubicin (DOX) is a commonly used chemotherapeutic drug for the treatment of breast cancer, leukemia, and other malignancies, but its use is limited by the severe toxic side effects, which may cause cardiomyopathy and heart failure.(285) Ferroptosis inhibitors can pr”
Anthracycline Chemotherapy and Cardiotoxicity (2017, background): “Until recently, the most widely accepted hypothesis was that anthracyclines interfered with redox cycling, resulting in DNA damage due to reactive oxygen species (ROS) production [14].”
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy (2004, neutral): “Sudden death 3 (0.4) 0 (0) 0 (0) 3 (5) Cardiac death 2 (0.3) 0 (0) 0 (0) 2 (3) Acute pulmonary edema 3 (0.4) 0 (0) 1 (0.7) 2 (3) Heart failure 47 (7) 1 (0.2) 18 (12) 28 (44) Asymptomatic left ventricular dysfunction 37 (5) 2 (0.4) 24 (17) 11 (17) Life-threatening arrhythmias 17 (2) 2 (0.4) 10 (7) 5 ”